In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Faux foie gras firm forms foodie panel
In Paris, cultivated meat startup Gourmey has formed what it claims is the culinary industry’s first-ever advisory board dedicated to cultivated meat.
The panel...
Celleste Bio secures $4.5 million for cell-cultured cocoa
In Israel, cell cultured cocoa startup Celleste Bio has raised $4.5 million in a seed funding round. The funds will boost the company's research...
Wrapped up: Origami inspires paperboard packaging solution
In Finland, researchers from VTT and Aalto University are applying origami, the ancient Japanese art of paper folding, to the plastics waste crisis.
Led...